- UroToday Home
- Trials in Progress
Trials in Progress
64Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA for Identification and Treatment of PSMA-expressing mCRPC (SECuRE)
Trials in Progress
A Phase I/IIa Theranostic Study of 64Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA for Identification and Treatment of PSMA-expressing Metastatic Castrate Resistant Prostate Cancer
- Condition: Prostatic Neoplasms, Castration-Resistant
- Study ID: NCT04868604
Publications
Articles and Abstracts
Clarity Update: Complete Response in First Patient Ever Treated with 2 Doses of Cu-67 SAR-bisPSMA at 8GBq
- A complete response, based on Response Evaluation Criteria In Solid Tumours (RECIST v1.1) assessment, has been reported from the first patient with metastatic castrate-resistant prostate cancer (mCRPC) to ever receive two cycles of Clarity’s 67Cu-SAR-bisPSMA at the 8GBq dose level.
SECuRE Update: First Participant Treated in the Last Cohort of Dose Escalation
- First participant in cohort 4 (first multi-dose cohort) in the theranostic SECuRE trial has been treated with 67Cu-SAR-bisPSMA at 12GBq.
- The SECuRE trial is investigating 64Cu/67Cu-SAR-bisPSMA in metastatic castrate-resistant prostate cancer (mCRPC) patients. Fifteen patients have been treated so far at 3 different dose levels of 67Cu-SAR-bisPSMA (single cycle): 4, 8 and 12GBq.
Clarity’s Theranostic Prostate Cancer Trial Advances to Multi-Dose Phase
- Cohort 3 of the theranostic SECuRE trial investigating 64Cu/67Cu-SAR-bisPSMA in metastatic castrate-resistant prostate cancer (mCRPC) has been completed in 6 participants who received therapy with 67Cu-SAR-bisPSMA at the highest single dose level of 12GBq.
First Patient with Metastatic Prostate Cancer to Receive 2 Doses of Cu-67 SAR-bisPSMA Achieves Undetectable PSA Level
- Undetectable levels of Prostate Specific Antigen (PSA) have been reported from the first patient with metastatic castrate-resistant prostate cancer (mCRPC) to ever receive two cycles of Clarity’s 67Cu-SAR-bisPSMA at the 8GBq dose level. PSA is a marker of tumour burden, clinical response to treatment and an indicator of the recurrence of disease for prostate cancer.
Clarity's Theranostic Prostate Cancer Trial Progresses at the Highest Dose Level Cohort
- Cohort 3 of the theranostic SECuRE trial investigating 64Cu/67Cu-SAR-bisPSMA in metastatic castrate-resistant prostate cancer (mCRPC) has enrolled and treated 3 participants who received therapy with 67Cu-SAR-bisPSMA at the highest dose level of 12GBq.
First Participant Treated at the Highest Dose Level in Clarity’s Theranostic Prostate Cancer Trial
- First participant of cohort 3 in the theranostic SECuRE trial investigating 64Cu/67Cu SAR-bisPSMA in metastatic castrate-resistant prostate cancer (mCRPC) has been treated at the highest dose level of 12GBq.
- Cohort 2 was recently completed in 3 participants who received therapy with 67Cu SAR-bisPSMA at the dose level of 8GBq.
Recruitment for the Dosimetry Phase of Clarity’s Cu-64/Cu-67 SAR-bisPSMA Theranostic Prostate Cancer Trial Completed
- Clarity Pharmaceuticals completes recruitment for the initial dosimetry phase of its SAR-bisPSMA theranostic clinical trial SECuRE (NCT04868604)1 investigating Targeted Copper Theranostics (TCT) in patients with metastatic castrate-resistant prostate cancer (mCRPC).
Conference Coverage
Conference Highlights Written by Physician-Scientist
ASCO 2024: SECuRE: A Dose Escalation/Expansion Study to Assess the Anti-Tumor Efficacy of 67Cu-SAR-bisPSMA in Patients with Metastatic Castrate Resistant Prostate Cancer
Presented by Geoffrey Johnson, MD, PhD,
Dr. Geoffrey Johnson presented SECuRE, a dose escalation/expansion study assessing the anti-tumor efficacy of 67Cu-SAR-bisPSMA in patients with metastatic castrate-resistant prostate cancer (mCRPC). Read More
ASCO GU 2024: SECuRE: A Dose Escalation/Expansion Study to Assess the Anti-tumor Efficacy of 67Cu-SAR-BisPSMA in Patients With mCRPC
Presented by Geoffrey Johnson, MD, PhD
During the 2024 ASCO GU cancers symposium, Dr. Geoffrey Johnson presented the study framework of SECuRE, a dose escalation/expansion study to assess the anti-tumor efficacy of 67Cu-SAR-bisPSMA in patients with metastatic castrate-resistant prostate cancer (mCRPC). Read More